Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Sponsor
Tulane University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05014802
Collaborator
(none)
50
3
18
16.7
0.9

Study Details

Study Description

Brief Summary

The study aims to evaluate and compare the incidence of atrial arrhythmias (including Post-Operative Atrial Fibrillation (POAF), atrial flutter, and atrial tachycardia) stratified by baseline Utah fibrosis stages and overall fibrosis (%) of the left atrial wall area. The investigators hypothesize that patients with a higher baseline Utah fibrosis staging will experience a higher incidence of POAF.

The study also aims to evaluate and compare the in-hospital mortality, length-of-stay (LOS), complication rates (strokes, pneumonia, respiratory failure etc.) of the different Utah fibrosis stage cohorts. Perform cost analysis and compare between patients with POAF and patients without POAF. The investigators hypothesize that patients experiencing POAF will have a higher mortality rate, longer LOS, greater complications, and therefore, additional hospital costs.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study is a a prospective, observational cohort study. 50 patients undergoing cardiac surgery (Coronary Artery Bypass Graft (CABG), valvular etc.) without a history of atrial fibrillation will be given a baseline Magnetic Resonance Imaging (MRI) upon which patients will be assigned Utah stages I-IV based on their left atrial fibrosis pattern. Overall fibrosis (%) of the left atrial wall area will also be collected. Patients will then undergo their planned surgeries receiving management adherent to current guidelines and standard of care procedures. Atrial arrhythmia incidence after surgical procedure will be collected using in-hospital telemetry or serial Electrocardiogram (ECG) from all patients in their respective cohorts. Cardiac surgery type, duration and any intraoperative complications will be recorded. Other clinical and relevant demographical data will be collected at admission and throughout patients' hospital stay.

    All cardiac surgeries will be performed by experienced surgeons at Tulane Medical Center, Washington University Medical Center Barnes Jewish Hospital, and University Medical Center New Orleans, adhering to all relevant standard-of-care guidelines. MRI imaging will be performed by experienced technicians and operators at Tulane Medical Center, Washington University Medical Center Barnes Jewish Hospital, and University Medical Center New Orleans. MRI Utah fibrosis staging will be performed and assessed by experienced operators at MARREK, Inc., by using the Corview processing software with de-identified images.

    The investigators expect a total recruitment of 50 subjects over a period of 6 months from the Tulane Medical Center Cardiology and Cardiothoracic Surgery Clinics, Washington University Medical Center Barnes Jewish Hospital Cardiology and Cardiothoracic Surgery Clinics, as well as University Medical Center New Orleans Cardiology and Cardiothoracic Surgery Clinics in order to complete the study. They expect to recruit 40 patients from Washington University Medical Center and 10 patients from either Tulane Medical Center or University Medical Center New Orleans.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: A Pilot Study for SAPPORO-AF
    Anticipated Study Start Date :
    Nov 1, 2022
    Anticipated Primary Completion Date :
    Nov 1, 2023
    Anticipated Study Completion Date :
    May 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of atrial arrhythmia in patients after cardiac surgery [2 weeks]

      The incidence of any atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia etc.) from after their surgical procedure to their discharge from the hospital. Atrial arrhythmia is defined as any abnormal atrial rhythm episode continuing for more than 30 seconds, starting immediately after the patient arrives at the post-operation ICU. All atrial arrhythmia starting after the operation will be monitored and recorded. This will be measured using continuous telemetry and/or serial ECG monitoring.

    Secondary Outcome Measures

    1. Rate of in-hospital mortality [2 weeks]

      In-hospital mortality is defined as patient death during any point of hospital stay following cardiac surgery. This will be measured through patients medical chart review.

    2. Hospital and Intensive Care Unit (ICU) length of stay (LOS) [2 weeks]

      LOS is defined as duration from admission to discharge in days in the hospital and ICU. This will be measured through patients medical chart review.

    3. Incidence of stroke [2 weeks]

      Stroke is defined as sudden loss of brain function caused by an interruption of blood supply to the brain either through an ischemic or hemorrhagic modality. This will be measured through patients medical chart review.

    4. Incidence of acute respiratory failure [2 weeks]

      Acute respiratory failure is any decrease in respiratory function resulting in hypoxemia (low arterial oxygen levels), hypercapnia (elevated levels of carbon dioxide gas) or a combination of the two. This will be measured through patients medical chart review.

    5. Incidence of sudden cardiac arrest [2 weeks]

      Sudden cardiac arrest is the abrupt loss of heart function, breathing and consciousness. This will be measured through patients medical chart review.

    6. Incidence of shock [2 weeks]

      Shock is a critical condition brought on by the sudden drop in blood flow through the body. This will be measured through patients medical chart review.

    7. Incidence of systemic or pulmonary embolism [2 weeks]

      An embolus is a blood clot that forms in the systemic or pulmonary circulation that jeopardizes normal blood flow to the area causing organ dysfunction. This will be measured through patients medical chart review.

    8. Incidence of infection post surgery [2 weeks]

      Infection is the invasion and multiplication of microorganisms in any area of the body, specifically the heart, lungs, blood and gastrointestinal and urinary tract. This will be measured through patients medical chart review.

    9. Hospitalization costs to the patient [2 weeks]

      All costs related to the current episode of hospitalization including procedures, medication, personnel and machine time, calculated prior to insurance or Medicaid/Medicare discount. This will be obtained through hospital billing department.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 120 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female patients age 40 years of age or older

    • Patients with no history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) scheduled to undergo cardiac surgery (These surgeries include but are not limited to coronary artery bypass graft (CABG), valvular repair/reconstruction, aneurysm repair, and insertion of pacemaker).

    Exclusion Criteria:
    • Patients with a history of atrial arrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia)

    • Patients with a history of cardiac or open chest surgery

    • Patients with a history of catheter ablation

    • Patients under the age of 40

    • Patients with left ventricular assist device (LVAD) or scheduled to have LVAD implanted

    • Patients who have previously undergone extracorporeal membrane oxygenation (ECMO)

    • Patients who have undergone or will undergo heart transplantation

    • Patients with any health related Late Gadolinium Enhancement (LGE)-MRI contraindications (including previous allergic reaction to gadolinium, pacemakers, defibrillators, other devices/implants contraindicated for MRI)

    • Acute or chronic severe renal disease with a low glomerular filtration rate (GFR), <30 mL per minute per 1.73 m2 will be excluded from the trial. (A creatinine measurement should be available within the last 6 months. If not, a creatinine blood test will be drawn to assess for renal function before the MRI acquisition).

    • Patients weighing > 300 lbs. (MRI image quality decreases due to increased body mass index)

    • Patients currently pregnant or breastfeeding, or plan to become pregnant during the study period

    • Patients with cognitive impairment preventing them from giving informed consent will be excluded from the study

    • Patients who cannot read, speak, and/or understand English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tulane University Medical Center New Orleans Louisiana United States 70112
    2 University Medical Center New Orleans New Orleans Louisiana United States 70112
    3 Washington University Barnes-Jewish Hospital Saint Louis Missouri United States 63110

    Sponsors and Collaborators

    • Tulane University

    Investigators

    • Principal Investigator: Nassir Marrouche, MD, Tulane University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tulane University
    ClinicalTrials.gov Identifier:
    NCT05014802
    Other Study ID Numbers:
    • 2021-622
    First Posted:
    Aug 20, 2021
    Last Update Posted:
    Apr 7, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Tulane University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 7, 2022